An interventional study of rTMS in Attention-Deficit/Hyperactivity Disorder (ADHD), sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 9 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by University of Calgary · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Canada.
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, this one is the 63rd largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 64th registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →12 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada are open now. Recruiting first, the newest first:
Dar Clinical Research Inc. · Sites in Canada
Ages 65+
University of Calgary · Sites in Canada
Ages 10+ · Women only · Healthy volunteers
Holland Bloorview Kids Rehabilitation Hospital · Sites in Canada
Ages 8–17
Douglas Mental Health University Institute · Sites in Canada
Ages 9–25 · Healthy volunteers
University of Calgary · Sites in Canada
Ages 6–24
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 9 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 18 · Phase 4 17
First in 1999; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 72 across 1,439 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 108 across the 72 interventional studies, 195 across the 13 observational. Of the 57 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 85 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 4 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
6 of the studies in Attention Deficit Disorder with Hyperactivity with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07597707University of CalgaryInvestigating Health, Equity, and Resilience in Girls and Women With ADHD Across the Lifespan | 2026-12-31 |
| NCT05916339Daniel CouryAWARE: Management of ADHD in Autism Spectrum Disorder | 2027-01-01 |
| NCT07926776University of ManitobaSupporting Families of School-Aged Children With ADHD: A Dual-Generation Therapy Approach Through the BRIDGE Program | 2027-05-31 |
| NCT07710014Dar Clinical Research Inc.Evaluation of Foquest in Adults 65 Years and Older With ADHD | 2027-07-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.
Background \& Rationale Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. It has an estimated prevalence of 5% in children. Usually, ADHD in children is treated with stimulant medications, such as methylphenidate. However, these pharmacotherapy treatments have numerous unwanted side effects, including sleep disturbances, appetite changes, and emotional lability, and do not prove to be effective in every case.
A promising and alternative option for reducing ADHD symptoms is non-invasive brain stimulation. Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation which involves the application of a magnetic field to the skull to change the behaviour and function of underlying brain areas. In turn, rTMS leads to positive long-term changes in neurochemical activity, and while studies are limited, some have shown that rTMS can reduce ADHD symptoms in adolescents with ADHD.
Methods Design: Open label TMS trial Primary Outcome: To examine the effect of active rTMS to the right prefrontal cortex on attention as measured by the TEACh-2
Outline:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active repetitive TMS
Device: rTMS
Repetitive transcranial magnetic stimulation (rTMS)
TEACH-2
Test of everyday attention in children - 2. Direct assessment of attention abilities in children.
Time frame: Baseline to week 5
SNAP-18
Parent reporting of ADHD symptom severity
Time frame: 5 weeks and 52 weeks.
PedsQL
Self reporting of quality of life
Time frame: Baseline to week 5
Plan to share: Undecided — If we do make individual participant data (IPD) available to other researchers it will be in keeping with local provincial laws on health information privacy. Data (if available) will be provided upon request.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 21 months is below that.
Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →